COMMUNIQUÉS West-GlobeNewswire

-
Epitopea et Genevant Sciences annoncent une entente de collaboration
19/12/2024 -
Epitopea and Genevant Sciences Announce Collaboration Agreement
19/12/2024 -
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
19/12/2024 -
Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules
19/12/2024 -
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
19/12/2024 -
Lifecore Biomedical to Report Financial Results for Second Quarter of Fiscal 2025 on January 2, 2025
19/12/2024 -
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome
19/12/2024 -
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19/12/2024 -
Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options
19/12/2024 -
Aptose Announces Positive Decision by Nasdaq Hearings Panel
19/12/2024 -
OraSure Technologies Acquires Sherlock Biosciences
19/12/2024 -
CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel
19/12/2024 -
U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome
19/12/2024 -
Vittoria Biotherapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of VIPER-101
19/12/2024 -
Bluejay Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
19/12/2024 -
Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel
19/12/2024 -
Presse release: Jean-Paul Kress to join Sanofi's Board of Directors
19/12/2024 -
Communiqué de presse - Jean-Paul Kress rejoint le Conseil d’administration de Sanofi
19/12/2024 -
ONWARD Medical Receives FDA De Novo Classification and US Market Authorization for World’s First Non-Invasive Spinal Cord Stimulation System for People with Chronic Spinal Cord Injury
19/12/2024
Pages